Bibliography
- Berger WE. New approaches to managing asthma: a US perspective. Therap Clin Risk Management 2008;4:363-79
- Holtzman MJ. Drug development for asthma. Am J Resp Cell Mol Biol 2003;29:163-71
- Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003;178:347-55
- Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63
- Barnes PJ. New treatments for asthma. Eur J Int Med 2000;11:9-20
- Ishimura M, Suda M, Morizumi K, et al. Effects of KP-496, a novel dual antagonist at the cysteinyl leukotriene receptor 1 and the thromboxane A2; receptor, on airway obstruction in guinea pigs. Br J Pharmacol 2008;153:669-75
- Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206
- Kamath AV, Pavord ID, Ruparelia PR, et al. Is the neutrophil the key effector cell in severe asthma? Thorax 2005;60:529-30
- Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999;353:57-62
- Dahlen SE. 5-lipoxygenase inhibitors. In: New Drugs for Asthma, Allergy and COPD. Hansel TT, Barnes PJ, editors. Basel: Karger, 2001. p. 115-20
- Fox H. Anti-IgE in severe persistent allergic asthma. Respirology 2007;12(Suppl 3):S22-8
- Milgrom H, Fick RB, Su J, et al .Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-73
- Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe asthma. J Allergy Clin Immunol 2001;108:184-90
- Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
- Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;23:76-81
- Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;23:76-81
- Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309
- Chipps B, Buhl R, Beeh KM, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006;11:2201-8
- Weinbrenner A, Huneke D, Zschiesche M, et al. Circadidan rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide J Clin Endocrinol Metab 2002;87(5):2160-3
- Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999;160:237
- Larsen BB, Nielsen LP, Engelstatter R, et al. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003;58:207
- Gauvreau GM, Boulet LP, Postma DS, et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005;116:285
- Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma Allergy 2005;60:330
- Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94(6):557-752
- Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo 1997;11(9):1245-55
- Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-70
- Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol 2000;47:127
- Barnes PJ. New treatments for asthma. Eur J Int Med 2000;11:9-20
- Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008;155(3):288-90. Epub 2008 Jul 28
- Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 1999;36:453-496
- Egan RW, Umland SP, Cuss FM, Chapman RW. Biology of interleukin-5 and its relevance to allergic disease. Allergy 1996;51:71-81
- Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hypersonsiveness and the late asthmatic response. Lancet 2000;356:2144-8
- Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199
- Kips JC, O'Conner BJ, Langley SJ, et al. Effect of SCH55700, a humanised anti-human interleukin-5 antibody in severe persistent asthma – a pilot study. Am J Resp Crit Care Med 2003;167:1655-9
- Flood-Page P, Swenson C, Faiferman I, et al. International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71
- Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36
- Rothenberg ME, Klion AD, Roufosse FE, et al. Mepolizumab HES Study GroupTreatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358(12):1215-28
- Deshpande DA, Dogan S, Walseth TF, et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway. Am J Respir Cell Mol Biol 2004;31:36-42
- Chiba Y, Nakazawa S, Todoroki M, et al. Misawa MInterleukin-13 Augments Bronchial Smooth Muscle Contractility with an Upregulation of RhoA Protein. Am J Respir Cell Mol Biol 2008 [Epub ahead of print]
- Jiang H, Harris MB, Rothman P. IL-4/IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063-70
- Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:1816-23
- Ma Y, Hayglass KT, Becker AB, et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 2007;62(6):675-82
- Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-60
- Walsh GM. Targeting airway inflammation: novel therapies for the treatment of asthma. Current Medicinal Chemistry 2006;13:3105-11
- Bree A, Schlerman FJ, Wadanoli M, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 2007;119(5):1251-7
- O'Byrne PM, MD Inman, E Adelroth. Reassessing the Th2 cytokine basis of asthma, Trends Pharmacol Sci 2004;25:244-8
- Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370(9596):1422-31
- Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121:5-10
- Rabinowitz MH, Andrews RC, Becherer JD, et al. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem 2001;44:425
- Erin EM, Williams TJ, Barnes PJ, et al. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Inflamm Allergy 2002;1:201-14
- De Lucca GV, Kim UT, Johnson C, et al. Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. J Med Chem 2002;45:3794-804
- Suzuki K, Morokata T, Morihira K, et al. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. Biochem Biophys Res Commun 2006;339:1217-23
- Morokata T, Suzuki K, Masunaga Y, et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther 2006;317(1):244-50
- Wegmann M, Göggel R, Sel S, et al. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. Am J Respir Cell Mol Biol 2007;36(1):61-7
- Walsh GM, Robinson P, Wu P. Recent developments in targeting eosinophil Accumulation as a Novel Therapeutic Approach for Asthma. Open Allergy J 2008;1:35-41
- Avila PC, Boushey HA, Wong H, et al. Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses. Clin Exp Allergy 2004;34:77-84
- Beeh KM, Beier J, Meyer M, et al. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2006;19(4):233-41
- Chiba Y, Sato S, Misawa M. Inhibition of antigen-induced bronchial smooth muscle hyperresponsiveness by lovastatin in mice. J Smooth Muscle Res 2008;44(3-4):123-8
- Woodside DG, Vanderslice P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs 2008;22(2):85-100
- Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003;5:372-8
- Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61:729-34
- Walsh GM. Statins as Emerging treatments for asthma and COPD. Exp Rev Respir Med 2008;23:329-35
- Menzies D, Menzies D, Nair A, et al. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007;119:328-35